XNAS
BMEA
Market cap114mUSD
Jul 11, Last price
2.00USD
1D
3.63%
1Q
14.29%
IPO
-88.24%
Name
Biomea Fusion Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
27.52%
Rev. gr., 5y
%
Revenues
0k
Net income
-138m
L+18.06%
CFO
-120m
L+24.12%
Profile
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 144,070 | 130,336 | 84,896 | |||
Unusual Expense (Income) | ||||||
NOPBT | (144,070) | (130,336) | (84,896) | |||
NOPBT Margin | ||||||
Operating Taxes | (1,806) | |||||
Tax Rate | ||||||
NOPAT | (144,070) | (130,336) | (83,090) | |||
Net income | (138,426) 18.06% | (117,255) 46.53% | (80,022) 94.14% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 161,803 | 1,239 | ||||
BB yield | -32.67% | -0.50% | ||||
| Debt | ||||||
Debt current | 2,079 | 4,932 | 618 | |||
Long-term debt | 15,463 | 18,126 | 3,952 | |||
Deferred revenue | ||||||
Other long-term liabilities | (534) | |||||
Net debt | (40,737) | (153,808) | (109,181) | |||
| Cash flow | ||||||
Cash from operating activities | (119,894) | (96,592) | (62,417) | |||
CAPEX | (3,370) | (1,030) | ||||
Cash from investing activities | (362) | (2,220) | 27,341 | |||
Cash from financing activities | 1,668 | 163,798 | 1,239 | |||
FCF | (139,815) | (137,217) | (85,395) | |||
| Balance | ||||||
Cash | 58,279 | 176,866 | 113,400 | |||
Long term investments | 351 | |||||
Excess cash | 58,279 | 176,866 | 113,751 | |||
Stockholders' equity | (387,247) | (248,821) | (131,568) | |||
Invested Capital | 447,591 | 430,820 | 241,858 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 36,106 | 34,107 | 29,272 | |||
Price | 3.88 -73.28% | 14.52 72.24% | 8.43 13.15% | |||
Market cap | 140,090 -71.71% | 495,233 100.69% | 246,761 38.83% | |||
EV | 99,353 | 341,425 | 137,580 | |||
EBITDA | (144,070) | (128,821) | (84,205) | |||
EV/EBITDA | ||||||
Interest | 1,806 | |||||
Interest/NOPBT | ||||||